TAU scientists develop nano-vaccine for melanoma

Written on |

Injection of nanoparticle has proven effective in mouse models, researchers say

Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.

The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU. The results were published recently in Nature Nanotechnology.

Creating a nano-vaccine

Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”

The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.

“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”

A vaccine against cancer

The researchers then examined the effectiveness of the vaccine under three different conditions. First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.

Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.

Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.

“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”

related posts

Recruiting ‘Fighting Cells’ to Destroy Tumors

September 14, 2021

TAU Team Reverses Early Signs of Alzheimer’s

September 10, 2021

Nicotine Testing of Children Curbs Parents’ Smoking

September 5, 2021

The Silent Prophets

August 31, 2021

Want to Fall in Love? Step Outside in The Sun

August 30, 2021

First 3D-bioprinting of entire active tumor

August 18, 2021

New Warning Sign for Breast Cancer

August 6, 2021

COVID-19 Immunity Varies Among Genders and Age Groups

July 25, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

A world first: Technology that restores the sense of touch in nerves damaged as a result of amputation or injury

July 15, 2021

New nanotech from TAU produces “healthy” electric current from the human body itself

July 9, 2021

Want to Live a Long Life? Consider Investing in Your Marriage.

July 2, 2021

A world first: Targeted delivery of therapeutic RNAs only to cancer cells, with no harm caused to healthy cells

June 30, 2021

Combating Antibiotic Resistance

June 22, 2021

Diamonds in the Rough

June 3, 2021

How Will We Brave the Post-COVID Era?

May 31, 2021

Are We Getting to the Root of Cancer?

May 3, 2021

Optical Technology Generates Immediate Melanoma Diagnosis

April 27, 2021

Gut Healing

April 25, 2021

Could Your Smartphone Be Damaging Your Teeth?

April 4, 2021

The Quest for A Lifesaving Cure

March 16, 2021

A Healthier Alternative to Antibiotics

February 24, 2021

Children with Autism during Lockdown: Serious Implications for Behavior and Development

February 22, 2021

Cancer Breakthrough: Cells’ Uniqueness is Also Weakness

January 29, 2021

TAU Scientists Develop Innovative Therapy to Prevent Deafness

December 28, 2020

Two TAU Professors Win 2020 Nature Mentoring Award

December 28, 2020

Lack of Teacher Support during Pandemic Causes Acute Emotional Harm

December 4, 2020

New Discovery: Development of the Inner Ear in Embryos is Similar to Crystal Formation

November 26, 2020

In First, Aging Stopped in Humans: TAU Co-Study

November 23, 2020

TAU developed genome editing system destroys cancer cells

November 20, 2020

TAU Co-Study: “Green Revolution” Decreased Infant Mortality

November 17, 2020

Study: Women Suffer More from COVID-related Orofacial Pain

November 12, 2020

Global First: Center for Combating Pandemics

October 22, 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

October 12, 2020

Researchers Identified the Genetic Causes of Inherited Hearing Loss in the Jewish Population of Israel

September 30, 2020

Targeting Melanoma

September 9, 2020

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

September 8, 2020

Physical exercise can help improve both physical and mental health

August 31, 2020

New school for Biomedicine and Cancer Research at Tel Aviv University

August 13, 2020

An Experimental Drug for Alzheimer’s May Help Children with Autism

August 5, 2020

TAU Study: Stimulating Immune System Prevents Post-Surgery Metastasis

July 27, 2020

TAU Researcher Fights Epidemics Both Viral and Virtual

July 23, 2020

TAU study: Oxygen therapy improves cognitive function in seniors

July 16, 2020

TAU-led Team Destroys Cancer Cells with Ultrasound

July 9, 2020

New nanomedicines for mRNA therapeutics in breast cancer and heart failure

July 6, 2020

3D printed heart used to test life-saving drugs

June 29, 2020

Did climate change cause infections 6,000 years ago?

May 21, 2020

Accurate 3D imaging could significantly improve IVF treatments

May 18, 2020

TAU study finds widespread misinterpretation of gene expression data

December 26, 2019

Fibroblasts involved in healing spur tumor growth in cancer

December 23, 2019
Ontario and Western Canada

3130 Bathurst Street, Suite, 214, Toronto, ON | M6A 2A1 
Phone: 416.787.9930 | Toll Free: 833.32.CFTAU (22328)
Email: toronto@cftau.ca

Ottawa, Quebec and Atlantic Canada

6900 Boulevard Décarie, Suite 3480, Montreal, QC | H3X 2T8
Phone: 514.344.3417
Email: montreal@cftau.ca


© CFTAU  | all rights reserved
Charitable registration: 124035643RR0001

TO TOP